

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

01/23/01
TOWNSEND and TOWNSEND and CREW LLP

By: 

11
4 E / 1/22/01
PATENT
Attorney Docket No.: 15280P-001000US
Client Reference No.: E-160-98/0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of:

Peter L. Collins, et al.

Application No.: 09/291,894

Filed: April 13, 1999

For: PRODUCTION OF ATTENUATED
CHIMERIC RESPIRATORY
SYNCYTIAL VIRUS VACCINES
FROM CLONED NUCLEOTIDE
SEQUENCES



Examiner: B. Brumback

Art Unit: 1642

RECEIVED

JAN 26 2001

RESPONSE TO RESTRICTION REQUEST
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the Restriction Requirement dated December 20, 2000, which set forth the following groups of claims:

I. Claims 1-30, 35, and 46-65, drawn to chimeric human respiratory syncytial virus (RSV) and isolated polynucleotides comprising chimeric human RSV genomes, classified in class 424, subclass 211.1 and in class 536, subclass 23.72.

II. Claims 1, 22, and 31-33, drawn to chimeric RSV / parainfluenza virus, classified in class 424, subclass 199.1.

III. Claims 1 and 34, drawn to chimeric human and bovine or murine RSV, classified in class 424, subclass 202.1.